Advancing Clinical Care.
Empowering Healthcare Frontiers.
Hallow Frontier Partners (HFP), headquartered in Singapore, brings medical device manufacturers and medical software solutions to hospitals, clinics and partners across Asia. With 25 years of medical sales and marketing experience across Asia and globally, it pairs in-house software development with distribution partner networks within HFP across the regions covered.
Tell us what you need
Choose the closest description and we will open a short enquiry form. It goes to us by email and we reply directly.
Years of Market Mastery
Extensive clinical sales and commercialization leadership spanning public clusters and private hospital networks across Asia and worldwide.
Reference Filing Gateway
A single Singapore-anchored technical dossier tailored dynamically to accelerate compliance across every subsequent Asian territory.
Core Business Disciplines
Hardware and software synergy under one roof: physical device logistics and enterprise healthtech commercialization.
Our Name • Our Conviction
The Philosophy Behind HFP
The name holds the standard we want to be judged by: care treated as sacred, a willingness to work where markets are still being mapped, and relationships built to last.
HALLOW
We treat commercial integrity as our fundamental operational duty. In an industry where market access demands absolute accuracy, we deliver what we commit to—ensuring transparent regulatory clearances, robust operational infrastructure, and predictable growth across all regions that we operate in. Whether navigating public tertiary hospital tenders or scaling into private clinics, our word is our execution.
FRONTIER
In an evolving healthcare environment, sustainable growth requires deliberate navigation of fragmented markets. We deploy decades of operational excellence to identify optimal entry points, mitigate regulatory friction, and scale high-impact commercial strategies. Moving decisively away from crowded red-ocean competition, we chart uncharted territory—delivering innovative medical technologies and digital platforms into blue-ocean clinical sectors across all regions we operate in.
PARTNERS
True commercial partnership extends far beyond transactional distribution. We build institutional relationships founded on transparency, shared risk, and long-term market leadership. Rather than aggregating commoditized catalogs, we are deliberately methodical in selecting the international principals and healthcare networks we collaborate with. This selective approach guarantees our partners undivided executive attention, robust regulatory governance, and disciplined commercial execution at every stage of growth.
Where Products Are Used
Five Care Settings We Focus On
These are the care settings, and the kinds of products and software, where we bring manufacturers and software makers into Asia.
Hospitals
Public and private hospitals buy through tenders and procurement committees. We have 25 years of experience selling into both.
- Patient and vital-signs monitoring
- Diagnostic and imaging equipment
- Surgical instruments and consumables
- SaMD and medical software for clinical decision support
Specialist Clinics & Imaging Centres
Smaller teams with specific needs: precise equipment, and software that fits how the clinic already works.
- Specialty diagnostic equipment
- Imaging accessories
- Clinic workflow software
- SaMD and medical software for imaging and diagnostics
Primary Care & GPs
Community clinics and GP groups need dependable, affordable equipment and simple digital tools.
- Point-of-care diagnostics
- Wearables and digital health
- Practice and records software
- SaMD and medical software for screening and chronic care
Nursing Homes & Elder Care
Residents are vulnerable and staff are stretched. Safety-focused monitoring and simple tools matter most here.
- Remote and bedside monitoring
- Wearables
- Care-record software
- SaMD and medical software for remote monitoring
Veterinary Clinics & Hospitals
Veterinary practice increasingly uses the same classes of equipment and software as human medicine.
- Diagnostic and monitoring equipment
- Surgical consumables
- Practice management software
- SaMD and medical software for veterinary diagnostics
Tell us what you build
If your device or software fits one of these settings and you want to sell in Asia, we would like to hear from you.
Division I • Medical Devices
Medical Device Distribution
For manufacturers who want to sell in Asia without building a regional organisation first. We aim to handle the route from Singapore registration to delivery, across the full range of device classes.
Product-Solution Fit & TAM / SAM Alignment
Clinical Need vs. Economic Desire
- •Validate procedural pain points: does the device mitigate complications, reduce clinical length of stay, or eliminate blind insertion errors (e.g., sensor-guided NG tube verification)?
- •Map the economic buyer: identify whether procurement decisions rest with hospital value committees (cost-per-bedday reduction) or private clinics (throughput and out-of-pocket margin).
Quantified Market Sizing
- •TAM (Total Addressable Market): Overall regional capital and consumable spend within the therapeutic category across South Asia and APAC.
- •SAM (Serviceable Addressable Market): Addressable procedural volumes across targeted care tiers—Tertiary Public Hospitals, Private Specialist Centers, Ambulatory GPs, Nursing Homes, and Veterinary Practices.
- •SOM (Serviceable Obtainable Market): 3-year commercial capture target aligned with your sales force capacity and tender cycles.
Trajectory & Margin Viability
- •Determine product lifecycle dynamics: recurring single-use consumable versus capital hardware with recurring service/kit attachments.
Multi-Territory Regulatory Clearances & Timelines
Anchor Clearance
Months 0–3- •Singapore (HSA): Establish local GDPMDS (SS 620) compliance (2–3 months). Clear Class A via notification (immediate to 10 days); submit Class B (1–3 months) and Class C (3–6 months) via abridged routes.
Abridged Regional Routes via Reference Recognition
Months 3–6- •Malaysia (MDA): CAB verification and MDA abridged review (2–4 months for Class B; 4–7 months for Class C).
- •Thailand (Thai FDA): CSDT submission via reliance pathway (Class 2: 2–4 months; Class 3: 4–7 months).
- •Vietnam (MoH): Fast-track Decree 98 registration leveraging HSA reference approval (Class A/B: 1–2 months; Class C: 3–6 months).
Direct National Technical Clearances
Months 4–8- •India (CDSCO): Form MD-14/MD-15 import evaluation via authorized agent (Class B: 3–5 months; Class C: 4–7 months).
- •Indonesia (BPOM / MoH): Local IDAK/PAK holder review and CDAKB alignment (Class B: 3–5 months; Class C: 5–8 months).
Software Compliance Track
Parallel- •Complete cybersecurity (ISO 27001), patient data sovereignty checks, and Synapxe/NEHR interoperability verification for digital health/SaMD lines.
Go-To-Market Execution: Entry, Growth & Sustainability
Entry Phase
Months 0–12- •Secure clinical validation through 2–3 flagship tertiary academic centers.
- •Deploy direct technical specialists in Singapore to establish standard-of-care protocols and overcome clinical objections before channel handoff.
- •Use evaluation placements and reagent-rental agreements to bypass slow institutional capital budget approvals.
Growth Phase
Months 12–36- •Cascade adoption down from tertiary hospitals to community facilities, day surgery clinics, nursing homes, and veterinary networks.
- •Appoint and manage audited in-country distribution partners in Malaysia, Thailand, Vietnam, Indonesia, and India using Singapore as the operational and training hub.
- •Monitor and submit bids for Ministry of Health multi-year tender cycles 6 to 12 months in advance.
Sustainability Phase
Years 3–5+- •Razor-and-Blade Recurring Economics: Anchor long-term revenues on steady consumable reorders (e.g., tube placement sensors, specialized imaging kits) rather than one-off capital sales.
- •Software Integration Moat: Pair physical hardware with custom SaMD, remote monitoring, and clinic management integrations, making replacement by commodity hardware competitors operationally prohibitive.
- •Performance-Tied Exclusivity: Enforce minimum sales milestones in manufacturer distribution contracts to protect master territory rights across all operational markets.
Timelines are indicative and vary by product, device class and regulator.
Division II • Medical Software
Medical Software Distribution & Development
Devices increasingly need software around them, and software makers need a way into Asian hospitals. We work on both sides of that.
Medical Software Distribution
Expanding into fragmented healthcare markets demands more than statutory filings; it requires aggressive commercial discipline. Partnering with Hallow Frontier Partners provides global medical technology and SaMD innovators with a direct pipeline to revenue. We evaluate market fit, structure multi-tiered buyer engagement, and navigate institutional procurement hurdles across public healthcare clusters and private hospital networks. We align our success with your commercial growth—transforming regional market access into scalable, recurring revenue.
Custom Software & Integration
Accelerating adoption by tailoring international medical devices and SaMD solutions to regional clinical realities. We resolve domestic regulatory mandates, integrate with national health infrastructures, and customize commercial models to meet the exact procurement criteria of tertiary academic centers, private specialist groups, and community care providers.
How we take software to market
Product-Solution Fit & Market Sizing
Workflow Need vs. Economic Desire
- •Pain point: does the software cut documentation time, reduce clinical or administrative errors, improve patient throughput, or shorten length of stay?
- •Economic buyer: hospital IT and value committees weighing licence budgets and integration cost, or private clinics weighing subscription price and ease of onboarding.
Quantified Market Sizing
- •TAM: overall regional health-IT and clinical-software spend in the category across South Asia and APAC.
- •SAM: sites and seats across the care settings we can serve: tertiary hospitals, private specialist centres, GPs, nursing homes and veterinary practices.
- •SOM: a 3-year capture target matched to our implementation capacity and public procurement cycles.
Model & Margin Viability
- •Subscription or SaaS versus perpetual licence with maintenance, and what integration and support really cost to deliver.
Classification, Compliance & Interoperability
Classify Early
At the start- •Decide whether the software qualifies as a medical device (SaMD) in each market. Qualifying software follows a registration route; the rest does not.
Singapore as Anchor
- •Health Sciences Authority route where the software qualifies, with the same technical documentation reused for reference-based routes in other regulators.
Security, Data & Interoperability Track
Parallel- •Information-security controls (ISO 27001), patient-data residency and privacy checks, and interoperability with national health-record systems such as Singapore’s NEHR through open standards like HL7 FHIR.
Localise for Each Market
- •Language, data hosting, clinical terminology and local workflow adaptation before launch.
Go-to-Market & Development: Entry, Growth & Sustainability
Entry Phase
Year 1- •Secure proof-of-value pilots at a small number of flagship hospitals and clinics.
- •Place implementation specialists in Singapore to set up workflows and overcome clinical and IT objections.
- •Use time-limited pilots and subscription starts to avoid slow capital budget approvals.
Growth Phase
Years 1–3- •Cascade from tertiary hospitals to community facilities, day-surgery clinics, nursing homes and veterinary networks.
- •Appoint and manage audited in-country resellers and implementation partners, using Singapore as the operational and training hub.
- •Track public IT and health procurement cycles well ahead of bid dates.
Sustainability Phase
Year 3+- •Recurring revenue: anchor income on subscriptions, support and usage rather than one-off licences.
- •Integration moat: pair software with distributed devices, remote monitoring and clinic-management integrations so it is hard to replace.
- •Co-development: build custom modules and SaMD roadmaps with vendors and providers on a shared-risk basis.
- •Performance-tied exclusivity: set minimum milestones in vendor distribution contracts to protect territory rights.
Singapore first, then the region
Strategic Regional Agility
Bridging Market Gaps Across 10+ Territories and Growing
Expanding into Asia does not mean deploying a rigid, one-size-fits-all checklist. By combining the regulatory prestige of our Singapore headquarters with in-market channels across Hong Kong, Taiwan, Malaysia, Thailand, Indonesia, Vietnam, India, Cambodia, and Laos, we dynamically sequence rollouts where your product’s clinical utility, reimbursement readiness, and commercial upside align for immediate traction.
-
1
Assess the product
Classification, existing approvals, and where it fits in Asian care settings.
-
2
File in Singapore
Prepare and submit the dossier to the Health Sciences Authority.
-
3
Adapt for further markets
Reuse the same technical file for other Asian regulators instead of rebuilding from zero.
-
4
Reach customers
Registration is the paperwork; launch is the hard part. This is the step our experience is for.
Want to sell in Asia, or back the company that helps you?
Manufacturers and software vendors, tell us what you make. Investors, we are happy to talk through the model and where things stand.